Source: International Congress 2014 – Animal models in respiratory drug development
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. P. Peron, G. Moraes, A. Brito, E. Silveira, B. Rodrigues Jr., R. Avelino, B. Franco, G. Rossi, M. Pellaty, M. Zats, L. Evangelista, S. Halpern, R. Vieira, A. P. Oliveira (São Paulo, Brazil). Both intranasal and intraperitoneal administration of human tubal mesenchymal stem cells (htMSC) ameliorates experimental COPD model. Eur Respir J 2014; 44: Suppl. 58, 1792

Member's Comments

No comment yet.

Related content which might interest you: Synergistic effect of human tubal mesenchymal stem cell (htMSCs) and low level laser (LLL) therapy significantly reduces experimental COPD in mice Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Exogenous administration of bone marrow-derived stem cells in experimental COPD Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013 Pretreatment of human adipose derived mesenchymal stem cells with PPAR-γ agonist improved effects of regeneration in elastase induced emphysema mouse model Source: International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema Year: 2015 Effects of autologous mesenchymal stromal cell treatment for severe emphysema on lung tissue: A clinical trial Source: International Congress 2015 – The multiple facets of stem and progenitor cells in lung health and disease Year: 2015 Effect of low level laser (LLL) and mesenchymal stem cells (htMSCs) therapies on cigarette-induced lung inflammation in mice Source: Annual Congress 2013 –Tobacco use in different countries: crisis to disease Year: 2013 Intratracheal administration of bone marrow-derived mesenchymal stem cells ameliorates lung function Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016 Cell therapy by adipose stromal cells affect tracheal responsiveness and inflammatory responses in guinea pigs model of COPD Source: International Congress 2015 – New models for treating airway diseases Year: 2015 Development of a human COPD model-on-a-chip to mimic disease exacerbation (a small airway-on-a-chip model) Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Adipose derived stem cells ameliorate airway inflammation in mouse models of asthma Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Comparative effects of inhaled and intravenous mesenchymal stem cells in bleomycin-induced pulmonary fibrosis in rabbits Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013 Effect of roflumilast on airway remodeling in a murine model of chronic asthma Source: International Congress 2015 – New models for treating airway diseases Year: 2015 Repeated lipopolysaccharide stimulation causes corticosteroid insensitive inflammation in lung via phosphoinositide-3-kinase δ signaling Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Targeted lung denervation in the healthy sheep model - A potential treatment for COPD Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Inhaled corticosteroids (ICS) attenuates epithelial mesenchymal transition (EMT) in COPD: A key to understanding long term benefits? Source: Annual Congress 2012 - Basic and translational studies in COPD Year: 2012 Effect of simvastatin on steroid-resistence in human epithelial cultured cells: A preliminary study Source: International Congress 2015 – New models for treating airway diseases Year: 2015 Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Effect of mast cells degranulation blockade on the inflammatory response outcome in the COPD model Source: International Congress 2016 – New signalling pathways in COPD Year: 2016 Combining an epithelial repair factor and anti-fibrotic with a corticosteroid offers optimal treatment for the pathogenesis of allergic airways disease Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 COPD airway epithelium secretion attracts and activates neutrophils Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Cellular approach of salbutamol effects on chronic lung inflammation induced by OVA in murine model Source: Eur Respir J 2004; 24: Suppl. 48, 127s Year: 2004